Pharco Pharmaceuticals
Pharco Pharmaceuticals is Egypt's largest pharmaceutical manufacturer and MENA region leader, producing 450+ branded generics and affordable Hepatitis C therapies (Sofosbuvir, Ravidasvir) across 11 group companies, 8,000+ employees, and 50+ export markets.
- Company typePrivate
- Founded1983
- HeadquartersAlexandria, Egypt
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pharco Pharmaceuticals does
Pharco Pharmaceuticals is the largest pharmaceutical manufacturer in Egypt and the MENA region, operating a vertically integrated group of 11 companies with 8,000+ employees, 2.5 million+ daily pack production capacity, and exports to more than 50 countries. Founded in 1983 by Dr. Hassan Abbas Helmy and currently led by CEO Dr. Sherine Helmy, the Alexandria-headquartered group produces generics and branded generics across anti-infectives, cardiovascular, diabetes, respiratory, CNS, gastrointestinal, oncology, hormonal, and dermatology therapeutic areas, alongside specialty products such as Gratisovir (Sofosbuvir), Ravidasvir, Mirazid (antiparasitic), Pedyphar (diabetic foot), and Aloreed (psoriasis). Core manufacturing capabilities include the largest soft gelatin capsule facility in MENA (Safe Pharma, formerly RP Scherer Egypt) producing 1.5 billion+ capsules annually via rotary die technology, Egypt's first GMP-compliant Active Pharmaceutical Ingredients factory (Sofosbuvir API via non-infringing method), and dedicated beta-lactam/cephalosporin facilities under cGMP.
The business model combines volume generic manufacturing for domestic distribution through owned wholesaler Abou Kir Trading (9,000+ Egyptian pharmacies) and Romanian subsidiary Pharco Impex (4,000+ pharmacies) with government-tender-driven Hepatitis C eradication programs — most notably the Egyptian national campaign that screened 70 million people and cured 4 million+ patients, and a parallel Malaysia public-sector program via Pharmaniaga JV at US$300 per treatment course. Regulatory moats include WHO prequalification for Sofosbuvir, EU PIC/S certification, and inclusion of Ravidasvir on the WHO Essential Medicines List (2023). Revenue streams include pharmaceutical product sales (450+ brands) and the Tour n' Cure medical tourism program offering HCV treatment at under 20% of Western pricing.
Recent strategic posture is geographic and capital expansion: Ashmore Investment Saudi Arabia and SIDF acquired a minority stake in Pharco KSA to fund a 62,000 sqm manufacturing facility in Al Madinah Industrial City targeting 2027 commissioning, while the company continues to develop women's health, dermatology, and chronic disease portfolios alongside its core infectious-disease franchise.
Pharco Pharmaceuticals firmographics
Firmographics- Name
- Pharco Pharmaceuticals
- Legal name
- Pharco Pharmaceuticals
- Website
- https://pharco.org
- Company type
- Private
- Founded year
- 1983
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Pharco Pharmaceuticals is Egypt's largest pharmaceutical manufacturer and MENA region leader, producing 450+ branded generics and affordable Hepatitis C therapies (Sofosbuvir, Ravidasvir) across 11 group companies, 8,000+ employees, and 50+ export markets.
- Ownership category
- akta.pro rank
Pharco Pharmaceuticals industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Specialty Pharmaceutical Distributors (HLAIAJAB)
Keywords
Where Pharco Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Alexandria
- HQ country
- Egypt
- HQ region
- Africa
Offices5 records
Markets served
Pharco Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Pharco generates revenue through manufacturing and selling generics, branded generics, and licensed pharmaceutical products. The company produces over 450 brands covering most pharmacological groups including anti-infectives, cardiovascular, diabetes, respiratory, CNS, gastrointestinal, and oncology medications. Products are sold domestically in Egypt and exported to 50+ countries.
- Medical Tourism - Tour n' Cure: International patients visit Egypt for HCV treatment through the Tour n' Cure program, combining medical treatment with tourism at significantly reduced costs compared to Western prices (under 20% of international costs).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | One time/ perpetual license | HCV treatment affordable pricing for developing countries |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
Pharco Pharmaceuticals product offering
Product offeringCore offering
Pharco Pharmaceuticals manufactures and distributes generic and branded generic pharmaceutical products across multiple therapeutic areas (anti-infectives, cardiovascular, diabetes, respiratory, CNS, gastrointestinal, oncology, hormones). It produces finished dosage forms (soft gelatin capsules, tablets, injectables) and active pharmaceutical ingredients, with WHO-prequalified and EU PIC/S-certified facilities. The company supplies over 450 brands across 11 group entities, exporting to 50+ countries and operating a Hepatitis C eradication-focused medical tourism program (Tour n' Cure).
Product overview
Pharco Pharmaceuticals is the largest pharmaceutical manufacturer in Egypt and the MENA region, operating as a diversified pharmaceutical corporation with 11 subsidiary companies. The product portfolio centers on generic and branded generic pharmaceuticals across diverse therapeutic areas including Hepatitis C antivirals (Gratisovir/Sofosbuvir and Ravidasvir), antibiotics (Cephalosporins, Penicillins), cardiovascular medications, diabetes treatments, women's health products (25 hormonal care products including contraceptives), dermatology treatments (Pedyphar for diabetic foot, Aloreed for Psoriasis), antiparasitics (Mirazid), and comprehensive ranges covering antihistamines, CNS, gastrointestinal, musculoskeletal, oncology, respiratory, and vitamins/supplements. The company also operates the Tour n' Cure medical tourism program for Hepatitis C treatment. Key brands include Gratisovir, Ravidasvir, Cefaxone, Ciprofar, Spasmo Digestin, and Mirazid, with manufacturing across soft gelatin capsules, tablets, injectables, and active pharmaceutical ingredients.
Differentiator
Problem solved
Functional benefit
Products and services
- Gratisovir (Sofosbuvir) Affordable oral Hepatitis C treatment (400mg Sofosbuvir tablets), a nucleotide analog NS5B polymerase inhibitor for chronic hepatitis C infection. Used as core component of combination Hepatitis C therapy sold at approximately $300 per course in developing markets.
- Ravidasvir HCV NS5A inhibitor (PPI-668) used in combination with Sofosbuvir for pangenotypic treatment of chronic Hepatitis C infection. Achieves 97-100% cure rates in clinical trials; included on the WHO Essential Medicines List (2023); licensed for low- and middle-income countries through Medicines Patent Pool.
- Mirazid Soft gelatin capsules for the treatment of Bilharziasis (schistosomiasis), Fascioliasis and other parasitic infections.
- Pedyphar Topical ointment for the treatment of diabetic foot ulcers.
- Aloreed Topical ointment for the treatment of Psoriasis.
- Branded Generics Portfolio Portfolio of over 450 branded generic pharmaceuticals across multiple therapeutic areas including Antihistamines, Anti-infectives, Antipyretics, Antivirals, Blood Coagulation, Cardio Vascular System, Central Nervous System, Dermatology, Diabetes, Gastrointestinal Tract, Genito-urinary system, Gynaecology, Hormones and Systemic Corticosteroids, Hospital, Musculoskeletal, Oncology & Immunity, Respiratory, Sensory, Urology, Vitamins & Supplements. Includes named brands such as Cefaxone and Ciprofar.
- Tour n' Cure Medical Tourism Program Medical tourism initiative offering Hepatitis C patients from around the world complete treatment regimens combined with tourism opportunities in Egypt, priced at under 20% of international treatment costs with no waiting time.
- Women's Hormonal Care Product Line Set of 25 women's hormonal care products manufactured by Techno Pharma Egypt for contraception, hormonal support, and infertility treatment.
- Cephalosporin and Penicillin Antibiotics Portfolio (Cefaxone, Ciprofar) Portfolio of cephalosporin and penicillin antibiotics manufactured at Pharco B International, including branded products such as Cefaxone and Ciprofar, produced in dedicated sterile and non-sterile facilities to avoid cross-contamination.
Quantifiable outcome
- 97-100% cure rate for Hepatitis C with ravidasvir + sofosbuvir combination therapy
- +4 more outcomes
Companies that use Pharco Pharmaceuticals
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Pharco Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Pharco Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and major.
- Pharmaniaga (Malaysia)coreJoint venture between Pharmaniaga and Pharco Corp of Egypt to produce ravidasvir locally in Malaysia. Collaboration with DNDi to manufacture and supply new HCV treatment regimen sold for US $300 in Malaysian public sector.
- Medicines Patent Pool (MPP)coreLicense and technology transfer agreement covering affordable supply of ravidasvir (PPI-668) in certain low- and middle-income countries with high hepatitis prevalence, including Russia, Ukraine, Egypt, and Iran.
- Presidio Pharmaceuticals, Inc.coreExclusive license agreement for Presidio's HCV NS5A inhibitor PPI-668 (ravidasvir) for development and commercialization to treat HCV infection in Egypt. Agreement includes opportunity to expand licensed territory to additional MENA region countries.
- Batterjee Pharmaceuticals KSAmajorJoint venture established in Saudi Arabia with Batterjee Group and EIPICO to offer wide range of pharmaceutical products to the Saudi Arabian market.
- RP Scherer CorporationcorePartnership for soft gelatin capsule manufacturing technology. Establishment of R.P Scherer Egypt (now Safe Pharma), producing over 1.5 billion capsules annually using Rotary Die technology.
- Drugs for Neglected Diseases initiative (DNDi)corePharco and DNDi conducted clinical trials on ravidasvir + sofosbuvir in Malaysia and Thailand achieving 97% cure rates. DNDi licensed ravidasvir in low and middle income countries for affordable HCV treatment.
- Prime PharmamajorPartnership to initiate Tour n' Cure medical tourism program, encouraging patients worldwide to visit Egypt for HCV treatment with complete medical care and tourism experience.
- Italian Research and Development LaboratorycoreContracted with Italian R&D laboratory to manufacture affordable HCV treatment (Sofosbuvir) to ensure continuous supply of raw materials for HCV treatments.
Scale indicators13 records
Recent moves11 records
Expansion highlights6 records
Pharco Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi Arabia-based pharmaceutical manufacturer producing generics and branded generics, with strong domestic Saudi presence and Vision 2030-aligned localization strategy. Comparable to Pharco as a regional manufacturer competing for Saudi government tenders and Arabic-speaking-market share.
- Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer with broad generics and branded generics portfolio across MENA. Comparable to Pharco as a regional GCC manufacturer with similar therapeutic breadth and government-tender exposure.
- EVA Pharma: Egyptian pharmaceutical manufacturer focused on affordable medicines across generics, branded generics, and specialty therapies, with strong export presence across MENA and Africa. Closely comparable to Pharco in scale, therapeutic breadth, and emerging-markets focus.
- Tabuk Pharmaceuticals: Saudi Arabia-headquartered pharmaceutical manufacturer producing branded generics across cardiovascular, CNS, anti-infectives, and respiratory categories. Closely comparable to Pharco as a regional GCC manufacturer pursuing Vision 2030 localization and competing for the same Saudi government tenders.
- Cipla: Indian global pharmaceutical company with major presence in generics, anti-infectives, and respiratory therapies, strong across Africa and emerging markets. Comparable to Pharco as a leading emerging-markets generics manufacturer with WHO prequalification and a focus on affordable access.
- EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers, established in 1980, producing branded generics across multiple therapeutic areas. Direct competitor to Pharco in the Egyptian market and historically a joint-venture partner with Pharco in KSA through Batterjee Pharmaceuticals.
- Hikma Pharmaceuticals: Jordan-headquartered generic and specialty pharmaceutical manufacturer with major MENA and US presence, producing generics across anti-infectives, cardiovascular, and CNS. Comparable to Pharco as a MENA-rooted, multi-geography generics manufacturer targeting both emerging and regulated markets.
- Aspen Pharmacare: South African pharmaceutical manufacturer with leading presence across Africa and emerging markets, focused on generics and specialty branded products. Comparable to Pharco in the role of a large emerging-markets generics champion pursuing both volume and affordability-driven models.
Broad incumbents
- Aurobindo Pharma: Indian global generics manufacturer with major API and finished-dose capacity, exporting broadly to Africa, MENA, and other emerging markets. Comparable to Pharco's branded-generics-plus-API model targeting similar geographies and price points.
- Sun Pharmaceutical Industries: India's largest pharmaceutical company and a global leader in generics, with deep presence across emerging markets including MENA and Africa. Comparable to Pharco as a generics powerhouse pursuing emerging-markets volume, though at much larger global scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Pharco Pharmaceuticals social profiles
Digital presencePharco Pharmaceuticals compliance and trust
Trust signalCompliance3 records
Pharco Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pharco Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles4 records
Pharco Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries9 records
Pharco Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pharco Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pharco Pharmaceuticals
What does Pharco Pharmaceuticals do?
Pharco Pharmaceuticals manufactures and distributes generic and branded generic pharmaceutical products across multiple therapeutic areas (anti-infectives, cardiovascular, diabetes, respiratory, CNS, gastrointestinal, oncology, hormones). It produces finished dosage forms (soft gelatin capsules, tablets, injectables) and active pharmaceutical ingredients, with WHO-prequalified and EU PIC/S-certified facilities. The company supplies over 450 brands across 11 group entities, exporting to 50+ countries and operating a Hepatitis C eradication-focused medical tourism program (Tour n' Cure).
Is Pharco Pharmaceuticals a public or private company?
Pharco Pharmaceuticals is a private company. It is classified as family owned and is currently operating.
When was Pharco Pharmaceuticals founded?
Pharco Pharmaceuticals was founded in 1983. It employs 1 to 10 people.
Where is Pharco Pharmaceuticals based?
Pharco Pharmaceuticals is headquartered in Alexandria, Egypt, in the Africa region.
How does Pharco Pharmaceuticals make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are medical Tourism - Tour n' Cure.
Who are Pharco Pharmaceuticals's main competitors?
Direct peers on record are SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation), Julphar (Gulf Pharmaceutical Industries), EVA Pharma, Tabuk Pharmaceuticals, Cipla, EIPICO (Egyptian International Pharmaceutical Industries Company), Hikma Pharmaceuticals and Aspen Pharmacare. Broad incumbents are Aurobindo Pharma and Sun Pharmaceutical Industries.
Does Pharco Pharmaceuticals have an API?
No public API is recorded for Pharco Pharmaceuticals.
What industry is Pharco Pharmaceuticals in?
Pharco Pharmaceuticals's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.